Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
Updated
Cooperative agreement from the National Institutes of Health, open to small businesses. Closes Oct 10, 2028, 705 days left.
| Opportunity number | RFA-NS-28-012 |
|---|---|
| Agency | National Institutes of Health |
| Funding type | Cooperative agreement |
| Field | Health |
| Award ceiling | $2.5 million |
| Expected number of awards | 3 |
| Total program funding | $6.0 million |
| Cost sharing or matching | Not required |
| Assistance listing | 93.866, 93.NS1 |
| Posted | Nov 3, 2026 |
| Closes | Oct 10, 2028 (705 days left) |
| Add the deadline to | Google Calendar |
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and state controlled institutions of higher education
- Native American tribal governments (federally recognized)
- Public housing authorities and Indian housing authorities
- Native American tribal organizations (other than federally recognized tribal governments)
- Nonprofits with 501(c)(3) status, other than institutions of higher education
- Nonprofits without 501(c)(3) status, other than institutions of higher education
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others (see the eligibility notes)
Other Eligible ApplicantsEligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Description
This Notice of Funding Opportunity (NOFO) supports the translation of genome editing and other biologic therapies for Alzheimer's Disease-Related Dementias (ADRD). The program spans the full translational pipeline, from therapeutic lead optimization and drug product development through IND-enabling studies and early clinical evaluation. Supported activities may include optimization of editing constructs and delivery systems; assessment of bioactivity, target engagement, durability, pharmacokinetics, and bioavailability; demonstration of in vivo efficacy; execution of safety pharmacology and toxicology studies; and development of scalable manufacturing processes, formulation strategies, and quality attributes aligned with regulatory expectations.ADRD include Frontotemporal Dementia (FTD); Lewy Body Dementias (LBD), including Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia (PDD); Vascular Contributions to Cognitive Impairment and Dementia (VCID); and Multiple Etiology Dementias (MED).
Full announcement and how to apply on Grants.gov
Health grants right now
There are 356 open federal grants in health that small businesses may apply for; 30 close within 30 days. The median award ceiling is $500,000; this grant offers up to $2.5 million. The agencies offering the most are National Institutes of Health, Centers for Disease Control and Prevention - ERA and Bureau of Global Health Security and Diplomacy. Grants in this field stay open a median of 1031 days; this one is open for 707 days.
Other open grants in the same program
Under assistance listing 93.866, 93.NS1, the federal program this grant is paid from.
More open grants from the National Institutes of Health
347 open grants from this agency accept small businesses, with $415.4 million in total program funding listed.